- Preparation method of ticagrelor key chiral intermediate isomer impurity TGAD2
-
The invention relates to a method for preparing an isomer impurity TGA of a key optically active intermediate TGAD2 with ticagrelor. The method is protected Cbz. The method has the advantages of simple and mild reaction conditions, convenient post-treatme
- -
-
Paragraph 0030-0033
(2021/10/05)
-
- Preparation method of ticagrelor key chiral intermediate isomer impurity TGAD1
-
The invention relates to a method for preparing an isomer impurity TGA of a key optically active intermediate TGAD1 with ticagrelor. The method is protected Cbz. The method has the advantages of simple and mild reaction conditions, convenient post-treatme
- -
-
Paragraph 0033-0035
(2021/10/02)
-
- For [...] novel intermediate and its preparation method
-
The invention discloses a novel intermediate of ticagrelor, i.e., a compound represented by a formula (I), and a preparation method thereof. The preparation method for the compound represented by the formula (I) comprises a step of subjecting a compound represented by a formula (II) or a proper salt of the compound represented by the formula (II) and a compound represented by a formula (III) to a substitution reaction, wherein R in the formulas represents substituted or unsubstituted benzyl and benzoyl groups. The invention further discloses a preparation method for a ticagrelor compound represented by a formula (A) from the novel intermediate, i.e., the compound represented by the formula (I). The method for preparing ticagrelor from the novel intermediate has the advantages of short reaction time, easy and convenient post-treatment, high yield and high product purity.
- -
-
Paragraph 0035-0038
(2018/06/21)
-
- Method for preparing ticagrelor key intermediate
-
The invention relates to a chemical synthesis method of ticagrelor key intermediate 2-[[(3aR, 4S, 6R, 6aS)-6-aminotetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxolane-4-yl] oxy]ethanol (a key intermediate A). The method comprises the following steps: taking D-ribose as a raw material, and carrying out ten chemical reaction steps of 1-locus methylation and 2,3-loci isopropylidene protection, 4-locus derivatization, iodination, furan ring-opening, hydroxylamine reaction, palladium on carbon catalytic hydrogenation, amino Cbz protection, hydroxy protection, sodium borohydride reduction ester, Cbz removal protection and the like, thereby obtaining the key intermediate A. The raw materials are cheap and readily available, the preparation process is high in operability, steps of optical resolution, chiral induction and the like are avoided, the total yield is relatively high, and the product quality is better; particularly due to the use of sodium borohydride reduction ester, the preparation cost of ticagrelor is greatly reduced; and the method is suitable for large-scale industrial production.
- -
-
Paragraph 0023; 0046
(2017/02/17)
-
- Synthesis method of ticagrelor intermediate
-
The invention relates to a synthesis method of a ticagrelor intermediate, and in particular relates to a synthesis method of (3aS, 4R, 6S, 6aR)-tetrahydrogen-6-hydroxy-2,2-dimethyl-cyclopentane[d][1,3]-dioxolane-4-benzyl carbamate. The synthesis method of a resolving agent used in the synthesis is simple, the raw material is cheap and easy to obtain, the recycling method is simple, and the prepared compound is high in optical purity, high in yield and suitable for industrial production.
- -
-
Paragraph 0034; 0035; 0036; 0037
(2017/04/19)
-
- Synthesis and biological evaluation of ticagrelor derivatives as novel antiplatelet agents
-
Ticagrelor (1) is the first reversible P2Y12 receptor antagonist blocking adenine diphosphate (ADP)-induced platelet aggregation with rapid onset and offset of effects. In this study, synthesis of ticagrelor and its derivatives has been accomplished in a convergent way. The compound design was based on modifications of ticagrelor and its major metabolite (33) in order to ameliorate their pharmacokinetic properties and dosing profile. The final compounds (1a-g, 35a-g) were evaluated for their inhibitory effect on ADP-induced platelet aggregation in rats. The assay results showed that some compounds (e.g., 1b, 1d, 33, 35b, 35f) exhibited comparable potency with that of ticagrelor.
- Zhang, Hao,Liu, Jun,Zhang, Luyong,Kong, Lingyi,Yao, Hequan,Sun, Hongbin
-
supporting information; experimental part
p. 3598 - 3602
(2012/07/14)
-
- NEW INTERMEDIATES AND PROCESSES FOR PREPARING TICAGRELOR
-
The present invention is related to new intermediates and processes for preparing Ticagrelor disclosed in this patent application.
- -
-
Page/Page column 38
(2012/10/18)
-
- A PROCESS FOR THE PREPARATION OF BENZYL [(3AS,4R,6S,6AR)-6-HYDROXY-2,2- DIMETHYLTETRAHYDRO-3AH-CYCLOPENTA[D][1,3]DIOXOL]-4-YL]CARBAMATE AND INTERMEDIATES IN THE PROCESS
-
The present invention is directed to a process for the preparation of benzyl [(3a S,4R,6S,6a R)-6-hydroxy-2,2-dimethyltetrahydro-3a H-cyclopenta[d][1,3]dioxol-4- yl]carbamate (VI), (VI), to products of said process and the use thereof.
- -
-
Page/Page column 4; 14-15
(2012/12/13)
-
- OPTICALLY ACTIVE SALTS OF (3AR,4S,6R,6AS)-6-AMINO-2,2-DIMETHYLTETRAHYDRO-3AH- CYCLOPENTA-[D] [1,3]DIOXOL-4-OL AND A METHOD OF THEIR PREPARATION
-
Diastereomeric salts of the compound of formula I with D-(-)-mandelic and R-(-)-3- chloromandelic acid, a method of for the preparation thereof and their use in the synthesis of the drug ticagrelor.
- -
-
-
- CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR
-
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof.
- -
-
-
- From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis
-
Starting from adenosine triphosphate (ATP), the identification of a novel series of P2Y12 receptor antagonists and exploitation of their SAR is described. Modifications of the acidic side chain and the purine core and investigation of hydrophobic substituents led to a series of neutral molecules. The leading compound, 17 (AZD6140), is currently in a large phase III clinical trial for the treatment of acute coronary syndromes and prevention of thromboembolic clinical sequelae.
- Springthorpe, Brian,Bailey, Andrew,Barton, Patrick,Birkinshaw, Timothy N.,Bonnert, Roger V.,Brown, Roger C.,Chapman, David,Dixon, John,Guile, Simon D.,Humphries, Robert G.,Hunt, Simon F.,Ince, Francis,Ingall, Anthony H.,Kirk, Ian P.,Leeson, Paul D.,Leff, Paul,Lewis, Richard J.,Martin, Barrie P.,McGinnity, Dermot F.,Mortimore, Michael P.,Paine, Stuart W.,Pairaudeau, Garry,Patel, Anil,Rigby, Aaron J.,Riley, Robert J.,Teobald, Barry J.,Tomlinson, Wendy,Webborn, Peter J.H.,Willis, Paul A.
-
p. 6013 - 6018
(2008/04/02)
-
- Novel triazolo pyrimidine compounds
-
The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.
- -
-
-
- Triazolo(4,5-d)pyrimidine compounds
-
Triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. The compounds of the invention have the formula (I) as follows: wherein R, X and R1through R3are as defined in the specification.
- -
-
-